drugset / Trial / NCT02170727
A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1
NaSingle-groupOpen-labelTreatment
Summary
To demonstrate the effectiveness of Daclatasvir (DCV) 3 Direct Acting Antivirals (DAA) fixed dose combination in Genotype 1 Chronic Hepatitis C subjects.
Timeline
- Start
- 2014-06-26
- Primary completion
- 2015-06-12
- Completion
- 2015-09-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Asunaprevir | Small molecule | 200 mg | Oral |
| Subject | Beclabuvir | Small molecule | 75 mg | Oral |
| Subject | Daclatasvir | Small molecule | 30 mg | Oral |